Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
MWN-AI** Summary
Odyssey Health, Inc. (OTCQB: ODYY) is a technology and asset acquisition company dedicated to creating innovative, life-saving medical products. On August 26, 2025, the company announced significant progress in advancing its Save A Life (SAL) choking rescue device. This device is designed to address a critical health issue, with approximately 5,000 choking-related deaths occurring annually in the United States and over 100,000 emergency room visits each year resulting from such incidents.
The SAL device is a patented anti-choking mechanism that operates through a safe and effective vacuum system. It comprises a pump and a replaceable mouthpiece, allowing for easy insertion into a choking victim's mouth. The device is engineered to depress the tongue and facilitate a trauma-free application while delivering a precise vacuum to dislodge any lodged food or object in seconds. This rapid-response mechanism highlights its potential to save lives in emergency situations.
Odyssey Health's President and CEO, Michael Redmond, emphasized the company's commitment to progressing toward an FDA submission for the SAL device, expected in 2026. With a focus on leveraging unique assets and intellectual properties, Odyssey aims to enhance medical solutions that address critical clinical needs and present substantial market opportunities.
In summary, Odyssey Health, Inc. is positioning itself as a key player in the medical technology field, working towards the FDA approval of its innovative SAL device. This initiative reflects the company's mission to develop solutions that have the potential to significantly impact public health and safety. For more information, visit their website at https://www.odysseyhealthinc.com.
MWN-AI** Analysis
Odyssey Health, Inc. (OTCQB: ODYY) is making strides with its Save A Life (SAL) choking rescue device, positioning itself in a critical market segment aimed at reducing choking incidents, which cause approximately 5,000 deaths annually in the U.S. As the company progresses towards an FDA submission in 2026, investors should consider several key points before making decisions regarding their equity interests in Odyssey.
First, the innovative design of the SAL device—as a patented vacuum mechanism that promises quick and effective relief for choking—gives the company a potential competitive edge in a sector traditionally dominated by less sophisticated methods. The ability to provide trauma-free aid rapidly could resonate well with both consumers and healthcare professionals.
The market for anti-choking devices presents substantial growth potential, enhanced by increasing public awareness about choking hazards. With over 100,000 ER visits annually due to choking, there’s a clear demand for effective solutions. Investors might find it appealing that Odyssey’s product is not just a theoretical proposition but has progressed to the prototype stage, indicating a lower risk profile moving forward.
However, potential investors should remain mindful of risks. The forward-looking statements hint at uncertainties that could impact development timelines or regulatory approval. The FDA approval process can be a lengthy and unpredictable journey. Furthermore, funding remains a critical concern; without sufficient capital, progress could be stymied.
In conclusion, while there’s significant promise in Odyssey Health’s developments, a balanced approach is essential. Investors should weigh the innovative nature and market demand of the SAL device against potential regulatory and financial hurdles. Careful monitoring of funding developments and regulatory timelines will be prudent for those considering an investment in Odyssey Health, Inc.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY ) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update on the development of its Save A Life (“SAL”) choking rescue device. Odyssey has created a prototype device and now plans to continue the advancement of the product with the ultimate goal of filing a submission to the FDA for the life-saving choking rescue device.
The Save a Life anti-choking device is a patented, safe, and easy to use vacuum device for removing a lodged mass or bolus from the throat of a choking victim. The device includes a pump for creating a vacuum chamber which is connected seamlessly with a replaceable/disposable mouthpiece. In an emergency SAL may be easily inserted into the victim’s mouth which depresses the tongue providing a clear, trauma-free application. By pressing a button on the device, the device will deliver the appropriate amount of instantaneous vacuum to dislodge the mass or bolus in the throat without harm or damage to the victim. The application is instantly effective as the device is operational and effective in a matter of seconds.
“We plan to advance the development of our Save A Life choking rescue device with our eyes on an FDA submission in 2026,” commented Odyssey President and Chief Executive Officer Michael Redmond. With approximately 5,000 choking deaths annually in the US in 95% homes, and over 100,000 emergency room visits per year; the problem requires an easy to use, rapid response device.”
About Odyssey Health, Inc.
Odyssey Health, Inc. (OTCQB: ODYY ) is a technology company with a focus in the area of life saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
For more information, visit: https://www.odysseyhealthinc.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including appropriate funding for the Company, economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
FAQ**
How does Odyssey Group International Inc ODYY plan to secure funding for the continued development and eventual FDA submission of the Save A Life choking rescue device?
What specific clinical trials or studies will Odyssey Group International Inc ODYY conduct to demonstrate the efficacy and safety of the Save A Life device prior to its FDA submission?
In what ways does Odyssey Group International Inc ODYY intend to differentiate the Save A Life device from existing choking rescue products in the market?
What market strategies will Odyssey Group International Inc ODYY implement to promote and distribute the Save A Life device after receiving FDA approval?
**MWN-AI FAQ is based on asking OpenAI questions about Odyssey Group International Inc (OTC: ODYY).
NASDAQ: ODYY
ODYY Trading
3.97% G/L:
$0.055 Last:
23,706 Volume:
$0.0445 Open:
